Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

New York, New York--(Newsfile Corp. - September 2, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2022.

EQUITY ALERT: Rosen Law Firm Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Norther

ABBOTT LABORATORIES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT

NEW YORK--(BUSINESS WIRE)-- #ABT--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Abbott securities between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”). Investors ha

ABBOTT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Abbott Laboratories and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Abbott Laboratories (NYSE: ABT) resulting from allegations that Abbott may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Abbott securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The

EQUITY ALERT: Rosen Law Firm Encourages Abbott Laboratories Investors to Inquire About Class Action Investigation – ABT

San Diego, California--(Newsfile Corp. - September 1, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Abbott Laboratories (NYSE: ABT) common stock between February 19, 2021 to June 8, 2022, inclusive (the "Class Period") have until October 31, 2022 to seek appointment as lead plaintiff in Pembroke Pines Firefighters & Police Officers Pension Fund v. Abbott Laboratories, No. 22-cv-04661 (N.D. Ill.).

INVESTOR DEADLINE: Abbott Laboratories Investors with Substantial Losses Have Opportunity to Lead the Abbott Laboratories Class Action Lawsuit - ABT

AbbVie

CVS Health

Buying these stocks now could lead to dividend payments that grow for the rest of your life.

3 Dividend Stocks to Buy in September for Passive Income Generation

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Abbott business and prospects, resulting in its stock trading at inflated prices.

INVESTOR ALERT: Abbott Laboratories Investors with Substantial Losses Have Opportunity to Lead the Abbott Laboratories Class Action Lawsuit - ABT

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don't receive either a heart pump or heart transplant is less than one year The MOMENTUM 3 study showcases the significant survival benefits of Abbott's heart pump technology, particularly in a patient population with limited therapy options ABBOTT PARK, Ill., Aug. 29, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later stage disease.

New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients

Abbott Laboratories has restarted production of its Similac infant formula at the plant in Sturgis, Michigan at the center of the U.S. baby formula shortage.

Abbott restarts Similac infant formula production at Michigan facility

Archer-Daniels-Midland Company

Con Ed

Coca-Cola

McDonald's

Procter & Gamble

Exxon Mobil

While the always bullish Wall Street community is probably well aware that stocks are trading way above normal price-to-earnings levels on a forward and trailing basis, it always seems difficult for them to tell investors those hard facts.

Bear Market Rally Might Be Over: 7 Very Safe Dividend Aristocrats to Buy Right Now

We think healthcare companies Abbott stock (NYSE: ABT) and Baxter stock (NYSE: BAX) may offer similar returns over the next few years. Although BAX is trading at a comparatively lower valuation of 2.2x trailing revenues than 3.4x for Abbott, this gap in the valuation is justified given.

Abbott Stock And Its Sector Peer Likely To Offer Similar Returns

Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.

Abbott (ABT) to Offer New Treatment Option for Chronic Pain

Abbott's new Proclaim™ Plus spinal cord stimulation (SCS) system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain The system builds on the company's proprietary therapy, BurstDR™ stimulation, that works by mimicking natural patterns found in the brain1 to deliver superior pain relief2,3 and is preferred to traditional "tingling" tonic stimulation by 87% of patients4 The Proclaim Plus SCS System can be used in conjunction with Abbott's NeuroSphere™ Virtual Clinic, which allows people to connect with their doctor and receive remote programming adjustments from the comfort of their home* ABBOTT PARK, Ill., Aug. 23, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim™ Plus spinal cord stimulation (SCS) system featuring FlexBurst360™ therapy.

FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Down 0.7% Since Last Earnings Report: Can It Rebound?

Citigroup

Trade Desk

Based on the market's reactions, we could someday look back at Q2 earnings as a major inflection point for these three stocks.

3 Blowout Earnings Reports That Could Mark Turning Points

Costco

NVIDIA

Pure Storage

Diversification is the edge for any portfolio. Rising inflation is impacting discretionary consumer spending as households try to stretch their wallets.

Here is a Simple 4 Stock Portfolio that Can Outperform the Market

This Dividend King pays shareholders a market-beating dividend.

Should Dividend Investors Add This Stock to Their Portfolios?

U.S. healthcare company Abbott Laboratories plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment agency IDA Ireland said on Friday.

Abbott to add 1,000 jobs in $450 million Irish investment

American States Water

These companies aren't stingy when it comes to making rate hikes.

2 Dividend Kings That Have Hiked Their Payouts by More Than 50% in 5 Years

The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care Researchers used Abbott's i-STAT™ TBI Plasma test – the only FDA-cleared rapid test on a portable analyzer for concussion – and Abbott's core laboratory ARCHITECT instrument to measure two biomarkers in blood plasma associated with brain injury ABBOTT PARK, Ill., Aug. 11, 2022 /PRNewswire/ -- A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury (TBI).

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions

Dividend Aristocrat Abbott Laboratories is one of our favorite healthcare names. Abbott's dividend increases in recent years have been quite substantial, and the company yields a very nice 1.7% at the time of this writing.

Abbott Laboratories' Dividend Strength Is Top Notch

Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.

Should You Really Care About This Company's Short-Term Success?

Similar to JNJ, ABT is a broadly diversified medical device and healthcare company. It has received much attention for its strong performance during the COVID-19 pandemic. ABT stock is down 20% from its all-time high, and one can rightly question whether ABT is a useful addition to a dividend growth portfolio.

Abbott Laboratories: A Lesser Johnson & Johnson?

Two industry leaders join forces to empower people living with diabetes by providing information and insights to improve weight loss, glucose control and overall health Collaboration will create a seamless, integrated experience between Abbott's world-leading continuous glucose monitoring device1 and WeightWatchers' number one doctor-recommended weight loss program2 to help individuals better understand and manage their diabetes and weight ABBOTT PARK, Ill., Aug. 4, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) and WW International, Inc. ("WeightWatchers" or "WW") today announced a strategic partnership that will help people living with diabetes better understand and manage their diabetes and weight.

Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals

ABT is a diversified healthcare company with strong growth prospects, an impressive track record of shareholder returns, and a fortress balance sheet. The company is moving past its infant formula recall, and has promising new products that should drive meaningful growth.

News for Abbott Labs Stock (ABT)